The KRAS gene provides instructions for making a protein called K-Ras that is part of a signaling pathway known as the RAS/MAPK pathway. The protein relays signals from outside the cell to the cell's nucleus.

Nov 15, 2021 · As the most frequently mutated oncogene, Kirsten rat sarcoma viral oncogene homologue (KRAS) has attracted substantial attention. The understanding of KRAS is constantly being updated by numerous...

Apr 4, 2024 · The most frequently mutated of these oncogenic driver genes, called KRAS, is associated with some of the most fatal cancer types: lung, pancreatic and colorectal cancers.

Apr 18, 2024 · Herein, we outline RAS pathobiology with a focus on KRAS, illustrate therapeutic approaches across a variety of malignancies, including emphasis on the ‘on’ and ‘off’ switch allele-specific and...

Kristen rat sarcoma (KRAS) gene is one of the most common mutated oncogenes in solid tumors. Yet, KRAS inhibitors did not follow suit with the development of targeted therapy, for the structure of KRAS has been considered as being implausible to target for decades.

KRAS is one of the oncogenic proteins and best well-known GTPase proteins. Although KRAS serves as regulation of cellular process, abnormal mutated and GTP-bound KRAS is highly expressed in human cancers. Understanding biological characteristics and ...

Jan 13, 2025 · KRAS is one of the most mutated genes, driving alternations in metabolic pathways that include enhanced nutrient uptaking, increased glycolysis, elevated glutaminolysis, and heightened synthesis of fatty acids and nucleotides. However, the beyond mechanisms of KRAS-modulated cancer metabolisms remain incompletely understood. In this review, we aim …

KRAS is a small GTPase that is among the most commonly mutated oncogenes in cancer. Here, we discuss KRAS biology, therapeutic avenues to target it, and mechanisms of resistance that tumors employ in response to KRAS inhibition.

Jan 17, 2025 · The U.S. Food and Drug Administration has approved sotorasib in combination with panitumumab for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer.

KRAS Kickers is a lung cancer research advocate community. KRAS is the most common biomarker associated with lung, colorectal, plus other cancers. Find resources to help with treatment.

Dec 25, 2024 · KRAS (KRAS Proto-Oncogene, GTPase) is a Protein Coding gene. Diseases associated with KRAS include Schimmelpenning-Feuerstein-Mims Syndrome and Oculoectodermal Syndrome. Among its related pathways are Downstream signaling of activated FGFR2 and Prolactin Signaling.

Jan 22, 2025 · Dr. Erin Schenk explains what KRAS mutation is in lung cancer. KRAS is an important biomarker that can impact lung what treatment options. Talk to your doctor about comprehensive biomarker testing.

A gene that makes a protein that is involved in cell signaling pathways that control cell growth, cell maturation, and cell death. The natural, unchanged form of the gene is called wild-type KRAS.

Feb 12, 2021 · KRAS mutations are present in approximately 25% of tumors, making them one of the most common gene mutations linked to cancer. They are frequent drivers in lung, colorectal and pancreatic cancers. KRAS drives 32% of lung cancers, 40% of colorectal cancers, and 85% to 90% of pancreatic cancer cases.

In this review article, we provide an overview on the role of K-RAS in tumorigenesis, past approaches to inhibiting Kras, and current and future prospects for targeting Kras.

Jan 12, 2023 · Now, results from a new study in mice have identified a promising experimental drug that directly targets pancreatic tumors with a particular KRAS mutation known as G12D. …

In this minireview, my aim is to provide the reader an overview of the publicly available KRAS structural data, insights to conformational dynamics revealed by experiments and what we have learned from MD simulations.

Mar 4, 2023 · KRAS is the most commonly mutated oncogene in human cancer, with greatest frequency in non-small-cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer. Since the gene's discovery several decades ago it had been considered an undruggable target with many failed clinical trials.

KRAS is the most common biomarker associated with lung, colorectal, pancreatic plus other cancers. Identified 50 years ago, researchers have learned that different sub-types of KRAS respond to treatments differently.

Nov 15, 2021 · This review summarises the most recent understanding of fundamental aspects of KRAS, the relationship between the KRAS mutations and tumour immune evasion, and new progress in targeting KRAS, particularly KRAS (G12C).

This review provides an overview of the structure of KRAS and its characteristic signaling pathways. Additionally, we examine the problems associated with currently available KRAS inhibitors and discuss promising avenues for drug development. Keywords: KRAS, cancer, signaling pathway, inhibitors 1. Introduction

3 days ago · Background/Objectives: Colorectal cancer (CRC) remains a leading cause of cancer mortality globally, with KRAS mutations occurring in 30–40% of cases, contributing to poor prognosis and resistance to anti-EGFR therapy. This review explores the biological significance, clinical implications, and therapeutic targeting of KRAS mutations in CRC. Methods: A …

2 days ago · The FDA has approved Lumakras® with Vectibix® for the treatment of previously treated KRAS G12C-mutated metastatic colorectal cancer.

Jan 16, 2025 · The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur: On January 16, 2025, the Food and Drug Administration approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for adult patients with KRAS G12C-mutated metastatic ...